Acutaas Chemicals Regulatory Approval

Acutaas Chemicals Management Change

Acutaas Chemicals appointed Dr. Ashish Kumar Pandey as AVP Operations (Cluster Head, Units 2 & 3) and designated as SMP from November 2, 2026. Two existing GMs ceased to be SMP but continue in the company.

Acutaas Chemicals Earnings Call Transcript: Key Takeaways

Acutaas reports high-growth Q2 fueled by pharma intermediates and CDMO scaling, despite commodity chemical phase-outs.

Call

Guides 100% growth

Acutaas Chemicals Investor Presentation: Key Takeaways

Q2 FY27 revenue ₹4,369 Mn (+42.7% YoY), EBITDA ₹1,760 Mn (+84.6%, 40.3% margin), PAT ₹1,231 Mn (+71.4%). FY27 revenue guidance raised; South Korea semiconductor-chemicals facility inaugurated.

Call

Guides 30% growth

Acutaas Chemicals Results Update

Q2 FY27 revenue rose 42.7% YoY to ₹4,369 mn; PAT up 71.4% to ₹1,231 mn. Guidance raised to 30% revenue growth and 38-40% EBITDA margin.

Acutaas Chemicals Q2 FY27 Results: Net Profit ₹123.1 Cr, Up 71.2% YoY

Acutaas Chemicals Ltd reported revenue from operations of ₹436.9 Cr (+42.7% YoY) and net profit of ₹123.1 Cr (+71.2% YoY) for Q2 FY27.

Key figure

Net profit ₹123.1 Cr · +71.2% YoY

Acutaas Chemicals Financial Results

Acutaas Chemicals' board approved Q2 and half-year FY2027 unaudited results. The board meeting closed with no other material transaction disclosed.

Neogen Chemicals Regulatory Approval

Neogen Chemicals received GPCB's revocation of its Dahej plant direction and a CC&A amendment for manufacturing. The revocation is for three months with conditions attached.

Arihant Capital Markets Regulatory Approval

Arihant Capital Markets received SEBI in-principle approval to sponsor and set up a mutual fund. Final registration remains subject to SEBI's conditions.

Dr. Reddy's Laboratories Regulatory Approval

Dr. Reddy's Laboratories received marketing authorization from Brazil's ANVISA for its generic semaglutide injection. The approval targets Brazil's diabetes market, estimated at approximately USD 244.6 million.

Alembic Pharmaceuticals Regulatory Approval

Alembic Pharmaceuticals received USFDA final approval for its generic Olopatadine Hydrochloride Ophthalmic Solution 0.7% ANDA. The product's US market is estimated at $20 million, per IQVIA.

Emmbi Industries Regulatory Approval

SEBI exempted the Makrand and Rinku Appalwar business trusts from SAST takeover rules for an internal family share transfer. Control and promoter shareholding remain unchanged.

Bliss GVS Pharma Regulatory Approval

Bliss GVS Pharma's UK subsidiary Asterisk Lifesciences received MHRA marketing authorisation for Mesalazine 1g Suppositories. The approval lets the subsidiary market the product in the UK.